IRS1 and central nervous system cancer: In conclusion, our results are consistent with the hypothesis that miR‐497 as a glioma promoter, is significantly correlated with the TMZ resistance of human glioma cells by targeting the IGF1R/IRS1 pathway both in vitro and in vivo.